Aprea Therapeutics Inc expected to post a loss of 77 cents a share - Earnings Preview

Aprea Therapeutics

26/03/2024 11:01

* Aprea Therapeutics Inc  APRE.OQ   APRE.O  is expected
to show a
rise in quarterly revenue when it reports  results on March 28
(estimated) for the period ending December 31 2023
    * The Doylestown Pennsylvania-based  company is expected to
report
revenue of $110 thousand, according to the mean estimate from 3
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Aprea Therapeutics Inc
is for
a loss of 77 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aprea
Therapeutics Inc is $16.00​, above​ its last closing price
of $6.08. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -1.16       -1.16      -0.86     Beat    26.1
 Jun. 30 2023  -1.42       -1.42      -0.87     Beat    38.9
 Mar. 31 2023  -1.52       -1.50      -1.34     Beat    11​
 Dec. 31 2022  -4.04       -3.08      -0.92     Beat    70.1
 ​​Sep.        -9.20       -5.50      -2.40     Beat    56.4
 30 2022                                                
 Jun. 30 2022  -7.00       -7.50      -19.60    Missed  -161.3
                                                        ​
 Mar. 31 2022  -7.60       -7.60      -7.20     Beat    5.3
 Dec. 31 2021  -8.80       -8.80      -7.20     Beat    18.2
 This summary was machine generated March 26 at 11:01 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)